BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升

路透中文

Jan 13

BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升

1月13日 - ** Armata制药公司ARMP.A股价盘前上涨24.8%至8.26美元

** 该公司称，美国食品及药物管理局（FDA）同意其中期研究数据支持将名为AP-SA02的疗法转入后期试验

** AP-SA02正在用于治疗复杂的金黄色葡萄球菌菌血症，这是一种严重的血流感染，可扩散到器官并危及生命。

** 试验将检验该疗法是否优于目前的标准疗法

** ARMP表示，FDA还表示将考虑授予该疗法 "合格传染病产品 "称号，该称号可提供延长市场独占期等激励措施

** 阿玛塔公司预计将于2026年下半年开始试验

** ARMP在2025年上涨了222%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603368912"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603368912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603368912?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-13 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603368912","market":"us","top_or_hot":-1,"title":"BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升</title></head><body><p><span>1月13日</span><span> - </span>** Armata制药公司<span>ARMP.A</span>股价盘前上涨24.8%至8.26美元</p><p>** 该公司称，<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局（FDA）同意其中期研究数据支持将名为AP-SA02的疗法转入后期试验</p><p>** AP-SA02正在用于治疗复杂的金黄色葡萄球菌菌血症，这是一种严重的血流感染，可扩散到器官并危及生命。</p><p>** 试验将检验该疗法是否优于目前的标准疗法</p><p>** ARMP表示，FDA还表示将考虑授予该疗法 \"合格传染病产品 \"称号，该称号可提供延长市场独占期等激励措施</p><p>** 阿玛塔公司预计将于2026年下半年开始试验</p><p>** ARMP在2025年上涨了222%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-13 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升</title></head><body><p><span>1月13日</span><span> - </span>** Armata制药公司<span>ARMP.A</span>股价盘前上涨24.8%至8.26美元</p><p>** 该公司称，<a href=\"https://laohu8.com/S/USFD\">美国食品</a>及药物管理局（FDA）同意其中期研究数据支持将名为AP-SA02的疗法转入后期试验</p><p>** AP-SA02正在用于治疗复杂的金黄色葡萄球菌菌血症，这是一种严重的血流感染，可扩散到器官并危及生命。</p><p>** 试验将检验该疗法是否优于目前的标准疗法</p><p>** ARMP表示，FDA还表示将考虑授予该疗法 \"合格传染病产品 \"称号，该称号可提供延长市场独占期等激励措施</p><p>** 阿玛塔公司预计将于2026年下半年开始试验</p><p>** ARMP在2025年上涨了222%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INVA","symbol_name":"Innoviva, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL4S3YE11U:1","article_id":"2603368912","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603368912","pubTimestamp":1768307559,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升1月13日 - ** Armata制药公司ARMP.A股价盘前上涨24.8%至8.26美元** 该公司称，美国食品及药物管理局同意其中期研究数据支持将名为AP-SA02的疗法转入后期试验** AP-SA02正在用于治疗复杂的金黄色葡萄球菌菌血症，这是一种严重的血流感染，可扩散到器官并危及生命。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"INVA":"Innoviva, Inc.","BK4007":"制药","BK4139":"生物科技","ARMP":"Armata Pharmaceuticals, Inc."},"translate_title":"BUZZ-Armata Pharma jumps on US FDA approval of late-stage infection trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":0.9,"ARMP":0.9},"content_text":"BUZZ-Armata Pharma 因美国 FDA 批准晚期感染试验而跃升1月13日 - ** Armata制药公司ARMP.A股价盘前上涨24.8%至8.26美元** 该公司称，美国食品及药物管理局（FDA）同意其中期研究数据支持将名为AP-SA02的疗法转入后期试验** AP-SA02正在用于治疗复杂的金黄色葡萄球菌菌血症，这是一种严重的血流感染，可扩散到器官并危及生命。** 试验将检验该疗法是否优于目前的标准疗法** ARMP表示，FDA还表示将考虑授予该疗法 \"合格传染病产品 \"称号，该称号可提供延长市场独占期等激励措施** 阿玛塔公司预计将于2026年下半年开始试验** ARMP在2025年上涨了222%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}